Total Payments
$472,447
2022 Payments
$58.81
Companies
20
Transactions
451
Medicare Patients
1,319
Medicare Billing
$93,915
Payment Breakdown by Category
Other$221,294 (46.8%)
Research$165,997 (35.1%)
Travel$42,218 (8.9%)
Consulting$34,515 (7.3%)
Food & Beverage$8,383 (1.8%)
Education$39.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $221,295 | 85 | 46.8% |
| Unspecified | $165,997 | 31 | 35.1% |
| Travel and Lodging | $42,218 | 136 | 8.9% |
| Consulting Fee | $34,515 | 5 | 7.3% |
| Food and Beverage | $8,383 | 192 | 1.8% |
| Education | $39.27 | 2 | 0.0% |
Payments by Type
General
$306,450
420 transactions
Research
$165,997
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $165,187 | 198 | $0 (2022) |
| SANOFI US SERVICES INC. | $159,784 | 29 | $0 (2021) |
| Amgen Inc. | $66,489 | 108 | $0 (2022) |
| Novo Nordisk Inc | $53,765 | 31 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $16,108 | 18 | $0 (2019) |
| ARALEZ PHARMACEUTICALS US INC. | $5,918 | 10 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $3,377 | 19 | $0 (2022) |
| Kowa Pharmaceuticals America, Inc. | $636.57 | 16 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $297.79 | 3 | $0 (2017) |
| Esperion Therapeutics, Inc. | $279.23 | 5 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $58.81 | 4 | Amgen Inc. ($18.14) |
| 2021 | $7,861 | 22 | SANOFI US SERVICES INC. ($7,514) |
| 2020 | $46,963 | 35 | SANOFI US SERVICES INC. ($42,953) |
| 2019 | $131,915 | 101 | Merck Sharp & Dohme Corporation ($62,864) |
| 2018 | $170,496 | 142 | Merck Sharp & Dohme Corporation ($77,589) |
| 2017 | $115,152 | 147 | Amgen Inc. ($46,537) |
All Payment Transactions
451 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/27/2022 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/04/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Cardiology | ||||||
| 03/01/2022 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/23/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/09/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug), STEGLATRO | Food and Beverage | In-kind items and services | $8.21 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/03/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $13.83 | General |
| 11/02/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug), STEGLATRO | Food and Beverage | In-kind items and services | $5.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/24/2021 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), VERQUVO, STEGLATRO | Food and Beverage | In-kind items and services | $7.40 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/19/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Cardiology | ||||||
| 08/09/2021 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $440.43 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | ||||||
| 07/29/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $4.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/30/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $14.08 | General |
| Category: Cardiovascular | ||||||
| 06/17/2021 | Merck Sharp & Dohme Corporation | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $7.14 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/09/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.81 | General |
| 05/27/2021 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), VERQUVO, STEGLATRO | Food and Beverage | In-kind items and services | $7.04 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/06/2021 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), VERQUVO, STEGLATRO | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/04/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.68 | General |
| 05/03/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: DIABETES | ||||||
| 04/08/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $12.89 | General |
| 04/06/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Cardiology | ||||||
| 03/15/2021 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $7,073.65 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | ||||||
| 03/04/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $107.19 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/03/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/03/2021 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), VERQUVO, STEGLATRO | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/03/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | SANOFI US SERVICES INC. | $74,194 | 13 |
| Eff-CVOT | SANOFI US SERVICES INC. | $50,492 | 4 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular | SANOFI US SERVICES INC. | $35,098 | 12 |
| FOURIER OLE (Ph 4) | Amgen Inc. | $5,400 | 1 |
| OSLER2 Ph3 OLE | Amgen Inc. | $812.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 49 | 63 | $16,145 | $4,632 |
| 2022 | 9 | 452 | 531 | $170,262 | $33,563 |
| 2021 | 11 | 649 | 786 | $141,176 | $37,265 |
| 2020 | 4 | 169 | 309 | $74,057 | $18,455 |
Total Patients
1,319
Total Services
1,689
Medicare Billing
$93,915
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 31 | $10,385 | $2,717 | 26.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 32 | $5,760 | $1,915 | 33.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 88 | 131 | $23,580 | $7,129 | 30.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 133 | 133 | $80,997 | $6,802 | 8.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 60 | $16,500 | $4,256 | 25.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 52 | $13,260 | $4,105 | 31.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $11,500 | $3,487 | 30.3% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 40 | 41 | $9,610 | $3,156 | 32.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 28 | 28 | $8,948 | $2,917 | 32.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 40 | 50 | $4,970 | $1,454 | 29.3% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 11 | 13 | $897.00 | $255.23 | 28.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 173 | 258 | $71,236 | $18,476 | 25.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 38 | 58 | $21,750 | $7,215 | 33.2% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 82 | 86 | $15,996 | $4,338 | 27.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 57 | 64 | $11,966 | $2,890 | 24.1% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Facility | 2021 | 21 | 21 | $4,473 | $1,230 | 27.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 136 | 139 | $7,989 | $1,210 | 15.1% |
| 93288 | Evaluation of parameters of leadless, single, dual, or multiple lead pacemaker system with qualified health care professional analysis, review, and report | Office | 2021 | 26 | 26 | $2,512 | $579.66 | 23.1% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 57 | 75 | $1,800 | $456.40 | 25.4% |
| 93016 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring and physician supervision | Facility | 2021 | 21 | 21 | $1,344 | $348.00 | 25.9% |
| 93228 | Heart rhythm tracing, computer analysis, and interpretation of patient-triggered events greater than 24-hour ekg up to 30 days | Office | 2021 | 17 | 17 | $1,207 | $291.25 | 24.1% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2021 | 21 | 21 | $903.00 | $231.30 | 25.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 83 | 182 | $50,054 | $13,141 | 26.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 41 | 58 | $21,750 | $4,905 | 22.6% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 19 | 21 | $1,533 | $265.49 | 17.3% |
About Dr. Hal Roseman, M.D
Dr. Hal Roseman, M.D is a Cardiovascular Disease healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366541302.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hal Roseman, M.D has received a total of $472,447 in payments from pharmaceutical and medical device companies, with $58.81 received in 2022. These payments were reported across 451 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($221,295).
As a Medicare-enrolled provider, Roseman has provided services to 1,319 Medicare beneficiaries, totaling 1,689 services with total Medicare billing of $93,915. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Specialist
- Location Nashville, TN
- Active Since 09/22/2006
- Last Updated 08/06/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1366541302
Products in Payments
- STEGLATRO (Drug) $136,515
- Repatha (Biological) $66,138
- SAR439977 (Drug) $58,824
- NO PRODUCT DISCUSSED (Drug) $50,492
- Victoza (Drug) $44,589
- JANUVIA (Drug) $24,366
- PRALUENT ALIROCUMAB INJECTION (Biological) $8,510
- PRALUENT (Biological) $7,714
- ZONTIVITY (Drug) $5,899
- FARXIGA (Drug) $3,050
- Livalo (Drug) $636.57
- Prolia (Biological) $254.48
- NEXLIZET (Drug) $248.76
- BRILINTA (Drug) $233.15
- XARELTO (Drug) $174.81
- PRALUENT (Drug) $129.45
- ELIQUIS (Drug) $125.09
- INVOKANA (Drug) $122.98
- Corlanor (Drug) $97.03
- DISEASE STATE (Drug) $87.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Nashville
Stephen Fahrig, Md, MD
Cardiovascular Disease — Payments: $679,196
Cardiovascular Disease $679,196
Dr. Gregory Bashian, M.d, M.D
Cardiovascular Disease — Payments: $485,755
Cardiovascular Disease $485,755
Dr. Jimmy Kerrigan, Md, MD
Cardiovascular Disease — Payments: $414,382
Cardiovascular Disease $414,382
Dr. Colin Barker, M.d, M.D
Cardiovascular Disease — Payments: $393,788
Cardiovascular Disease $393,788
Joshua Beckman, Md, MD
Cardiovascular Disease — Payments: $201,658
Cardiovascular Disease $201,658
Dr. Arvindh Kanagasundram, M.d, M.D
Cardiovascular Disease — Payments: $193,333
Cardiovascular Disease $193,333